Skip to main content

Table 1 Patient characteristics, treatment and outcomes

From: Primary pancreatic lymphoma – pancreatic tumours that are potentially curable without resection, a retrospective review of four cases

  Case 1 Case 2 Case 3 Case 4
Age 64 70 56 61
Sex Male Male Male Male
Presenting Symptoms Abdominal pain, nausea, weight loss then jaundice Vomiting, weight loss Dyspepsia, weight loss Abdominal pain, weight loss then jaundice
Delay until diagnosis 5 weeks 3 months 18 months 4 months
Method of diagnosis Endoscopic ultrasound FNA Laparotomy Laparotomy Laparotomy
CT appearance 6 cm pancreatic mass with biliary obstruction and portal vein involvement Large peri-pancreatic mass 5 cm pancreatic mass Pancreatic mass and peripancreatic lymph nodes
Ca-19.9 level* 500 kU/L 50 kU/L Not available 39 kU/L
Pre-treatment LDH Normal Elevated Normal Elevated
Histology** DLBCL DLBCL Grade II follicular non-Hodgkins lymphoma DLBCL
Stage*** IIE IIE IIE IIE
Prognostic index Low-intermediate risk (IPI 2/5) Low-intermediate risk (IPI 2/5) Low risk (FLIPI 1/5) Low-intermediate risk (IPI 2/5)
Treatment R-CHOP * 4 then involved-field RT CHOP * 3 then involved-field RT Involved-field RT then CVP then rituximab 3 * CHOP then involved-field RT
Outcome NED at 23 months Local recurrence at 32 months post-diagnosis, with poor tolerance of 2nd line chemotherapy and rapid treatment-related death NED at 25 months Out of field recurrence at 21 months post diagnosis. Salvage chemotherapy and autologous SCT. NED at 64 months from diagnosis
  1. CHOP – Cyclophosphamide, doxorubicin, vincristine, prednisone
  2. CVP – Cyclophosphamide, vincristine, prednisone
  3. DLBCL – diffuse large B-cell non-Hodgkin's lymphoma
  4. FLIPI – Follicular lymphoma international prognostic index [8]
  5. IPI – International Prognostic Index for the Aggressive Non-Hodgkin's Lymphomas [7]
  6. NED – No evidence of disease
  7. R-CHOP – Rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone
  8. RT – Radiotherapy
  9. SCT – Stem cell transplantation
  10. * Normal Range 0–50 kU/L
  11. ** Histology defined according to REAL classification.[5]
  12. *** Staging defined according to Ann Arbor staging system.[4]
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us